(Q34273853)

1 August 2017

1 reference

title

Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations (English)

1 reference

1 August 2017

Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations (English)

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

attention deficit hyperactivity disorder

27 March 2024

main subject

pharmacotherapy

0 references

0 references

1 reference

John S. Markowitz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14594346

27 March 2024

Arthur B. Straughn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14594346

27 March 2024

Kennerly S. Patrick

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14594346

27 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

1 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1592%2Fphco.23.12.1281.32697

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

https://onlinelibrary.wiley.com/doi/full/10.1592/phco.23.12.1281.32697

27 March 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

27 March 2024

1 reference

1 August 2017

23

1 reference

1 August 2017

10

1 reference

1 August 2017

1281-1299

1 reference

Globalisation of international health

1 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Adolescent suicidality in urban minorities and its relationship to conduct disorders, depression, and separation anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Treatment of attention-deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Attention-deficit/hyperactivity disorder and comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Association of the dopamine transporter gene (DAT1) with poor methylphenidate response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Attention deficit hyperactivity disorder and the gene for dopamine Beta-hydroxylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Problems in the management of attention-deficit-hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Drug interactions with brain biogenic amines and the effects of amphetamine isomers on locomotor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

21 January 2018

Stimulant medications

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Methyiphenidate vs. amphetamine: Comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

"Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Short-term cardiovascular effects of methylphenidate and adderall

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Enantioselective behavioral effects of threo-methylphenidate in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Lessons from a bacterial cocaine esterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Single-Dose Pharmacokinetics of Methylphenidate in CYP2D6 Extensive and Poor Metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Role of P-glycoprotein in pharmacokinetics: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

The mammalian carboxylesterases: from molecules to functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacokinetics of methylphenidate in hyperkinetic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separation of dl-threo-methylphenidate, (Ritalin) using a macrocyclic antibiotic as the chiral selector

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Effects of food on the pharmacokinetics of methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Extended-release methylphenidate (Ritalin LA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Methylphenidate ER tablet lodging in esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Failed attempts at intranasal abuse of Concerta

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Enantiomeric drug development: issues, considerations, and regulatory requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.12.1281.32697

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder

27 March 2024

3

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

27 March 2024

7

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Adult psychiatric status of hyperactive boys grown up.

27 March 2024

8

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

27 March 2024

10

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research

27 March 2024

11

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Injuries to children with attention deficit hyperactivity disorder

27 March 2024

13

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

ADHD is associated with early initiation of cigarette smoking in children and adolescents

27 March 2024

14

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder

27 March 2024

17

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey.

27 March 2024

18

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Dopaminergic system genes in ADHD: toward a biological hypothesis

27 March 2024

19

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder

27 March 2024

32

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating

27 March 2024

36

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Anti-hyperactivity medication: methylphenidate and amphetamine

27 March 2024

54

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance

27 March 2024

55

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans

27 March 2024

65

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Synthesis and pharmacology of hydroxylated metabolites of methyl phenidate

27 March 2024

74

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

A study of methylphenidate in man with respect to its major metabolite

27 March 2024

77

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Pharmacokinetics of methylphenidate in man, rat and monkey

27 March 2024

79

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxymethylphenidate using deuterated internal standards

27 March 2024

86

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Gas chromatographic/mass spectrometric analysis of methylphenidate (ritalin) in serum

27 March 2024

99

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Sustained release methylphenidate: pharmacokinetic studies in ADDH males

27 March 2024

101

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation

27 March 2024

102

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Negative ion chemical ionization for the determination of methylphenidate in human plasma by stable isotope dilution gas chromatography/mass spectrometry

27 March 2024

103

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability

27 March 2024

104

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids

27 March 2024

109

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method

27 March 2024

112

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Enantioselective gas chromatographic assay with electron-capture detection for dl-ritalinic acid in plasma

27 March 2024

113

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers

27 March 2024

114

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder

27 March 2024

120

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.

27 March 2024

127

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.12.1281.32697

27 March 2024

Identifiers

1 reference

1 August 2017

1 reference